肝细胞癌组织中E2F8、PKD1表达与临床病理特征、上皮间质转化及预后的关系

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)组织中E2F转录因子8(E2F8)、蛋白激酶D1(PKD1)表达与临床病理特征、上皮间质转化(EMT)及预后的关系。方法选取2018年10月至2021年10月保定市第二医院收治的89例原发性肝癌患者,取术中切除的癌组织和癌旁组织标本,采用免疫组化法检测E2F8、PKD1蛋白以及EMT相关指标(上皮钙黏蛋白、N-钙黏蛋白、波形蛋白)。E2F8、PKD1蛋白表达与EMT相关指标的相关性采用Spearman相关性分析。不同E2F8、PKD1蛋白表达HCC患者生存曲线采用Kaplan-Meier法绘制,Cox比例风险模型分析患者预后的影响因素。结果与癌旁组织相比,癌组织E2F8蛋白(59.55% vs. 33.71%)、PKD1蛋白(52.81% vs. 25.84%)、N-钙黏蛋白(69.66% vs. 34.83%)、波形蛋白(65.17% vs. 30.34%)的阳性表达率增高(P<0.05);上皮钙黏蛋白(25.84% vs. 66.29%)的阳性表达率降低(P<0.05)。E2F8、PKD1蛋白表达与分化程度、CNLC分期、血管侵犯有关(P<0.05)。CNLC分期Ⅲa期、低分化、发生血管侵犯的HCC组织中,E2F8、PKD1蛋白阳性表达率更高(P<0.05)。HCC组织E2F8、PKD1蛋白表达与上皮钙黏蛋白表达呈负相关,与N-钙黏蛋白、波形蛋白表达呈正相关(P<0.05)。E2F8、PKD1蛋白阳性表达患者3年总生存率低于E2F8、PKD1蛋白阴性表达患者(45.28% vs. 60.61%、44.68% vs. 58.97%,P<0.05)。CNLC分期Ⅲa期、E2F8蛋白阳性表达、PKD1蛋白阳性表达是HCC患者预后不良的危险因素(P<0.05)。结论 HCC组织中,E2F8、PKD1蛋白阳性表达率增高与恶性临床病理特征及EMT密切相关,是患者预后不良的危险因素。

关键词: 肝细胞癌, E2F转录因子8, 蛋白激酶D1, 临床病理特征, 上皮间质转化, 预后

Abstract: Objective To investigate the relationship between E2F transcription factor 8 (E2F8) and protein kinase D1 (PKD1) expressions in hepatocellular carcinoma tissues and clinicopathological features, epithelial-mesenchymal transition (EMT) and prognosis. Methods 89 patients with primary liver cancer were admitted to Baoding Second Hospital from October 2018 to October 2021 were selected. The specimens of cancer tissues and adjacent tissues resected during operation were collected. E2F8, PKD1 protein and EMT related indicators [epithelial cadherins (E-cadherin), N cadherin (N-cadherin), vimentin (Vimentin)] were detected by immunohistochemical method. The correlation between E2F8, PKD1 protein expressions and EMT related indicators was analyzed by Spearman correlation analysis. Survival curves of hepatocellular carcinoma patients with different E2F8 and PKD1 protein expressions were drawn by Kaplan-Meier method, and the prognostic factors of patients with primary liver cancer were analyzed by Cox proportional risk model. Results Compared with adjacent tissues, the positive expression rates of E2F8 protein (59.55% vs. 33.71%), PKD1 protein (52.81% vs. 25.84%), N-cadherin protein (69.66% vs. 34.83%) and Vimentin protein (65.17% vs. 30.34%) in cancer tissues were increased (P<0.05), and the positive expression rates of E-cadherin protein (25.84% vs. 66.29%) were decreased (P<0.05).The E2F8 and PKD1 protein expressions were related to the degree of differentiation, CNLC stage and vascular invasion (P<0.05). The positive expression rates of E2F8 and PKD1 proteins in hepatocellular carcinoma tissues of CNLC stage Ⅲa, low differentiation and vascular invasion were higher (P<0.05). E2F8 and PKD1 protein expressions in primary liver cancer tissues were negatively correlated with E-cadherin protein,positively correlated with N-cadherin and Vimentin protein (P<0.05). The 3-year overall survival rate of patients with E2F8 and PKD1 protein positive expression was lower than those of patients with E2F8 and PKD1 protein negative expression (45.28% vs. 60.61%, 44.68% vs. 58.97%; P<0.05). CNLC stage Ⅲa, positive E2F8 protein expression and positive PKD1 protein expression were risk factors for poor prognosis in hepatocellular carcinoma patients (P<0.05). Conclusion The increased positive expression rates of E2F8 and PKD1 proteins in hepatocellular carcinoma are closely related to malignant clinicopathological features and EMT, which are risk factors for poor prognosis of hepatocellular carcinoma patients.

Key words: Hepatocellular carcinoma, E2F transcription factor 8, Protein kinase D1, Clinicopathological features, Epithelial-mesenchymal transition, Prognosis

王鹏, 冯娜欣, 刘泽阳, 庞新. 肝细胞癌组织中E2F8、PKD1表达与临床病理特征、上皮间质转化及预后的关系[J]. 肝脏, 2026, 31(7): 994-999.

Wang Peng, Feng Naxin, Liu Zeyang, Pang xin. Relationship between E2F8 and PKD1 expressions in hepatocellular carcinoma tissues and clinicopathological features, epithelial-mesenchymal transition and prognosis[J]. Chinese Hepatolgy, 2026, 31(7): 994-999.

/ 推荐

参考文献

[1] 马晓萱, 王荣琦. 代谢组学在肝细胞癌诊疗中的研究进展[J]. 中国全科医学, 2025, 28(8):1017-1022.
[2] 李玉强, 李男, 吴彬, 等. lncRNA HOTAIRM1与miR-125b对肝细胞癌生物学行为影响[J]. 锦州医科大学学报, 2022, 43(1):1-9, 16.
[3] Jian H Y, Zhang J T, Liu Z, et al. Amentoflavone reverses epithelial-mesenchymal transition in hepatocellular carcinoma cells by targeting p53 signalling pathway axis[J]. J Cell Mol Med, 2024, 28(11):e18442.
[4] 雷军, 陈健国, 吴金训, 等. 肝细胞肝癌组织NTS、SPNS2、Mortalin表达与上皮间质转化标志物、临床病理特征和预后的关系[J]. 现代生物医学进展, 2022, 22(19):3704-3708, 3698.
[5] Lee D Y, Chun J N, Cho M, et al. Emerging role of E2F8 in human cancer[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(6):166745.
[6] 宋世伟, 李景武, 刘晓辉. miR-144-3p靶向E2F8抑制肺腺癌细胞的增殖和侵袭并阻滞细胞周期[J]. 生命科学研究, 2023, 27(6):479-487.
[7] 王怡婷, 李志平, 盛思琪, 等. E2F8在人结直肠癌中的表达及其与患者预后的关系[J]. 医学研究与战创伤救治, 2024, 37(3):261-266.
[8] Kim L K, Park S A, Eoh K J, et al. E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer[J]. Int J Biol Sci, 2020, 16(2):320-329.
[9] Fleming Martinez A K, Storz P. Protein kinase D1-A targetable mediator of pancreatic cancer development[J]. Biochim Biophys Acta Mol Cell Res, 2024, 1871(2):119646.
[10] 陈红利, 崔博淼, 康颖竹, 等. 不同分化程度的口腔鳞状细胞癌组织中蛋白激酶D的表达[J]. 四川大学学报(医学版), 2020, 51(6):755-759.
[11] Du Y, Lv D, Cui B, et al. Protein kinase D1 induced epithelial-mesenchymal transition and invasion in salivary adenoid cystic carcinoma via E-cadherin/Snail regulation[J]. Oral Dis, 2022, 28(6):1539-1554.
[12] 张蓉, 张婕, 潘亚杰. 不同中国肝癌分期患者肝癌根治性切除术后的临床疗效差异与预后影响因素[J]. 实用癌症杂志, 2023, 38(2):240-242.
[13] Chan Y T, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma[J]. Mol Cancer, 2024, 23(1):189.
[14] 张子涵, 黄金刚, 邱世香, 等. 血清HIF-1α、HSP27、HSP70、HSP90α与肝细胞癌患者经肝动脉化疗栓塞术治疗疗效的关系研究[J]. 现代生物医学进展, 2024, 24(4):695-700.
[15] Fu R, Xue W, Liang J, et al. SOAT1 regulates cholesterol metabolism to induce EMT in hepatocellular carcinoma[J]. Cell Death Dis, 2024, 15(5):325.
[16] 张丽瑾, 罗梦珺, 陈涛, 等. 上皮-间质转化在肝癌中的作用及中药干预的研究进展[J]. 生命的化学, 2022, 42(2):332-337.
[17] Liang J, Yao N, Deng B, et al. GINS1 promotes ZEB1-mediated epithelial-mesenchymal transition and tumor metastasis via β-catenin signaling in hepatocellular carcinoma[J]. J Cell Physiol, 2024, 239(5):e31237.
[18] Wu Y, Peng L. Circ_0084615 promotes epithelial-mesenchymal transition-mediated tumor progression in hepatocellular carcinoma[J]. Ann Gastroenterol Surg, 2024, 8(6):1107-1117.
[19] Luo M, Xie L, Lin B, et al. Mechanism study of E2F8 activation of SPC25-mediated glutamine metabolism promoting immune escape in lung adenocarcinoma[J]. Immunology, 2025, 174(4):450-461.
[20] Li H, Sun J, Hu H, et al. Transcription factor E2F8 activates PDK1-mediated DNA damage repair to enhance cisplatin resistance in lung adenocarcinoma[J]. Pharmacology, 2024, 109(6):341-356.
[21] Lee D Y, Lee S, Kim Y S, et al. Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK dependent manner[J]. Oncol Rep, 2023, 50(6):218.
[22] Zhang M, Xu Y, Zhang Y, et al. E2F8 knockdown suppresses cell proliferation and induces cell cycle arrest via Wnt/beta-catenin pathway in ovarian cancerr[J]. Chin J Physiol, 2023, 66(4):266-275.
[23] Li X Q, Cao Z R, Deng M, et al. E2F8-TPX2 axis regulates glycolysis and angiogenesis to promote progression and reduce chemosensitivity of liver cancer[J]. Cytotechnology, 2024, 76(6):817-832.
[24] Kong J, Xu S, Zhang P, et al. Transcription factor E2F8 promotes cisplatin resistance in hepatocellular carcinoma by regulating DNA damage via NUSAP1[J]. Int J Toxicol, 2023, 42(5):420-429.
[25] Eoh K J, Kim H J, Lee J W, et al. E2F8 induces cell proliferation and invasion through the epithelial-mesenchymal transition and Notch signaling pathways in ovarian cancer[J]. Int J Mol Sci, 2020, 21(16):5813.
[26] Ahn H R, Kim S, Baek G O, et al. Effect of sortilin1 on promoting angiogenesis and systemic metastasis in hepatocellular carcinoma via the notch signaling pathway and CD133[J]. Cell Death Dis, 2024, 15(8):634.
[27] Zhan P, Lu Y, Lu J, et al. The activation of the notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma[J]. Sci Rep, 2024, 14(1):22859.
[28] Li G, Fan M, Zheng Z, et al. Osteoblastic protein kinase D1 contributes to the prostate cancer cells dormancy via GAS6-circadian clock signaling[J]. Biochim Biophys Acta Mol Cell Res, 2022, 1869(9):119296.
[29] Luo Q, Li J, Miao H, et al. circSSPO boosts growth of esophageal squamous cell carcinoma through upregulation of micrRNA-6820-5p-mediated KLK8 and PKD1 expression[J]. Cell Biol Toxicol, 2023, 39(6):3219-3234.
[30] 丁祺, 杨红玉, 孙亚楠, 等. 血清HSP70、PKD1、YKL-40对绝经后早期子宫内膜癌淋巴结转移的预测效能[J]. 广西医科大学学报, 2024, 41(1):92-97.
[31] Ge J, Zhang X, Zhang B, et al. Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients[J]. Clin Res Hepatol Gastroenterol. 2021, 45(6):101573.
[32] Guo Y, Jiang Y, Rose J B, et al. Protein kinase D1 signaling in cancer stem cells with epithelial-mesenchymal plasticity[J]. Cells, 2022, 11(23):3885.